Providing superior bioanalytical services since 2000.

Welcome to Alturas Analytics

Founded in 2000, Alturas Analytics was launched by a core team of bioanalytical experts driven to create a premier contract research organization (CRO) focused on LC-MS/MS bioanalysis. The team made a commitment to unmatched quality science and excellent customer service that they still uphold today. Our Laboratory Director, Dr. Shane Needham, provided the burgeoning business with the bulk of the LC-MS/MS bioanalytical expertise. A former scientist at Pfizer, Dr. Needham acquired extensive experience with the first mass spectrometer in industry sold by AB Sciex, and has continually demonstrated a propensity to push the boundaries of bioanalytical methods and applications in the realms of chromatography and mass spectrometry. Our President, Robin Woods, had already contributed to the genesis and continued success of two environmental testing laboratories and agreed to provide her own extensive experience and business acumen to the venture. 

Commitment to excellence in all things is reflected in those that have joined our ranks over the years, and this combined vision and dedication to providing the best service possible has yielded strong, well-managed growth that will continue into the future. Over the past year, Alturas invested in 3 additional LC-MS/MS systems, including another SCIEX Triple Quad LC-MS/MS 6500 to add to our suite of high performance
instruments. The latest, most sensitive instrument from Sciex, a Triple Quad LC-MS/MS 6500+, is planned for installation before the end of 2017. The SCIEX 6500s introduce a series of advancements that increase ion production and transmission efficiency to the detector yielding greater sensitivity. This brings a high degree of redundancy and increased capacity for projects that require ultimate sensitivity such as highly potent drugs and topical formulations where concentrations in the peripheral circulation are typically in the low pg/mL range. With an increase in the development of highly specific and targeted drugs, Alturas is prepared to address the demand with the latest technology teamed with knowledge and experience. All of this in an innovative, purpose-built laboratory facility situated in idyllic Moscow, Idaho, USA.

Our location in the pacific northwest affords us many luxuries and a quality of life that are hard to come by elsewhere, and our close proximity to two major research universities, major highways and interstate thoroughfares in combination with two local, dedicated airports keep Alturas well connected to the rest of the world. Alturas enjoys working with a diverse clientele, ranging from virtual startups to many of the most dominant pharmaceutical, biotechnology and medical device manufacturers in the world. We credit our success to our laboratory expertise, highly motivated team of skilled scientists and our unsurpassed commitment to quality and customer service.

Alturas is a privately owned company, and greatly enjoys the freedom this provides to focus on fostering strong and lasting relationships with our sponsors while retaining the flexibility needed to accommodate their unique needs as they arise. From our scientific operations to our quality assurance unit (QAU), the Alturas staff has the skills and experience to adapt to changing timelines and rapid turnarounds for sample analysis and data delivery.

At Alturas we also have a long-standing dedication to intensive research and sequester 15% of our annual resources to the development of new bioanalytical applications and technologies. For example, Alturas developed Dried Blood Spot (DBS) technology for use with bioanalytically challenging translucent fluids. Through the creation of a novel dye, our scientists were able to successfully analyze a host of troublesome matrices such as tears, urine, cerebral spinal fluid and synovial fluid; all extracted from spotted cards. Alturas continues to lead the industry into the future in its research of the advantages of microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS).

 Click here to learn about our latest research.

Take a Tour

meet our team

Our research intensive team continues to lead the industry in bioanalytical support of early drug discovery, toxicology and clinical studies while building relationships with our clients through the outstanding customer service that they have come to expect.

Chad ChristiansonSenior Scientist

As a senior scientist at Alturas Analytics, Inc. Chad’s primary focus is LC-MS/MS method development, validation and sample analysis for...Read more

Robin WoodsPresident

Robin became a cofounder of Alturas Analytics, Inc. in 2000. As president, Robin manages the business operations side of Alturas Analytics as...Read more

Bo ChengIT Manager

Bo oversees all of Alturas Analytics IT operations. Bo ensures that data is stored, transferred and archived safely and securely to keep your information safe. Read more

Shane R. NeedhamLaboratory Director

Dr. Needham has over 20 years of LC/MS and analytical lab experience in the drug discovery through drug development stage in... Read more

Becky KoehlerQuality Assurance Manager

As the quality Assurance Manager at Alturas Analytics Becky’s primary focus is ensuring the laboratory compliance with FDA good laboratory practice...Read more

Jennifer ZimmerLaboratory Manager

Dr. Zimmer is responsible for the overall operations of the Alturas Analytics laboratory. She oversees the generation of quality assays, data and reports as...Read more

Alturas Advisor

The 2017-18 Alturas Advisor is out! Have a look to learn about business and throughput innovations that enhance proficiency and efficiency in our bioanaytical lab.

Download Now